[1]周騰騰,鄭 瑩,梁恵卿,等.蛋白質組學在慢性乙型肝炎常見中醫證型中的研究[J].醫學信息,2019,(20):30-32,36.[doi:10.3969/j.issn.1006-1959.2019.20.009]
 ZHOU Teng-teng,ZHENG Ying,LIANG Hui-qing,et al.Study on Proteomics in Common TCM Syndromes of Chronic Hepatitis B[J].Medical Information,2019,(20):30-32,36.[doi:10.3969/j.issn.1006-1959.2019.20.009]
點擊復制

蛋白質組學在慢性乙型肝炎常見中醫證型中的研究()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年20期
頁碼:
30-32,36
欄目:
綜述
出版日期:
2019-10-15

文章信息/Info

Title:
Study on Proteomics in Common TCM Syndromes of Chronic Hepatitis B
文章編號:
1006-1959(2019)20-0030-04
作者:
周騰騰1鄭 瑩2梁恵卿2唐金模2
(1.福建中醫藥大學,福建 福州 351012;2.福建中醫藥大學附屬廈門中醫院,福建 廈門 361009)
Author(s):
ZHOU Teng-teng1ZHENG Ying2LIANG Hui-qing2TANG Jin-mo2
(1.Fujian University of Traditional Chinese Medicine,Fuzhou 351012,Fujian,China;2.Xiamen Traditional Chinese Medicine Hospital,Fujian University of Traditional Chinese Medicine,Xiamen 361009,Fujian,China)
關鍵詞:
蛋白質組學慢性乙型肝炎中醫證型
Keywords:
Proteomics Chronic hepatitis B TCM syndromes
分類號:
R259
DOI:
10.3969/j.issn.1006-1959.2019.20.009
文獻標志碼:
A
摘要:
蛋白質組學逐漸成為系統性認知疾病的一種重要方法,該方法從整體角度分析不同狀態下細胞內的動態變化,與中醫的整體觀一致,在研究中醫證候中顯示出獨特優勢,并在認識多種疾病的中醫證候上取得進展。目前蛋白質組學在研究慢性乙型肝炎發病機制及預后上取得一定成果,在慢性乙型肝炎常見中醫證型差異上也取得進展。本文主要對蛋白質組學在慢性乙型肝炎常見中醫證型中的研究做一綜述。
Abstract:
Proteomics has gradually become an important method for systemic cognitive diseases. This method analyzes the dynamic changes in cells under different conditions from a holistic perspective. It is consistent with the overall view of TCM and shows unique advantages in the study of TCM syndromes. And made progress in understanding TCM syndromes of various diseases. At present, proteomics has made progress in studying the pathogenesis and prognosis of chronic hepatitis B, and has made progress in the differences in common TCM syndrome types of chronic hepatitis B. This article reviews the research of proteomics in common TCM syndromes of chronic hepatitis B.

參考文獻/References:

[1]王貴強,王福生,成軍,等.慢性乙型肝炎防治指南(2015年版)[J].中國肝臟病雜志(電子版),2015,7(3):1-18. [2]劉二麗,汪曉軍.451例慢性乙型病毒性肝炎患者中醫證型分布及與臨床檢驗指標的相關性[J].中華中醫藥雜志,2019,34(4):1793-1795. [3]Temnov AA,Rogov KA,Sklifas AN,et al.Protective properties of the cultured stem cellproteome studied in an animal model of acetaminophen-inducedacuteliverfailure[J].Mol Biol Rep,2019, 46(3):3101-3112 [4]Yue X,Guidry JJ.Differential Protein Expression Profiles of Bronchoalveolar Lavage Fluid Following Lipopolysaccharide-Induced Direct and Indirect Lung Injury in Mice[J].Int J Mol Sci,2019,20(14):E3401. [5]Pandey A,Mann M.Proteomics to study genes and genomics[J].Nature,2000,405(6788):837-846. [6]Ding C,Li Y,Guo F,et al.A Cell-type-resolved Liver Proteome[J].Mol Cell Proteomics,2016,15(10):3190-3202. [7]Dapic I,Baljeu-Neuman L,Uwugiaren N,et al.Proteome analysis of tissues by mass spectrometry[J].Mass Spectrom Rev,2019,38(4-5):403-441. [8]朱明丹,杜武勛,姜民,等.中醫證候與基因、蛋白質、代謝組學研究思路探討[J].中國中醫基礎醫學雜志,2010,16(1):69-71. [9]周紅光,陳海彬,周學平,等.蛋白質組學是中醫病機研究的重要技術平臺[J].中國中西醫結合雜志,2012,32(7):990-993. [10]陳少宗,齊向華,祝世訥.系統中醫學視域下的中醫精準醫療[J].山東中醫雜志,2019(6):503-507,518. [11]胡小勤,曾學文,岑衛健,等.高血壓病氣虛血瘀證和肝陽上亢證比較蛋白質組學初步研究[J].中華中醫藥雜志,2013,28(2):532-534. [12]熊新貴,梁清華,候俊良,等.高血壓腦出血肝陽化風證與肝陽上亢證患者血清蛋白質組學研究[J].實用預防醫學,2007,14(6):1649-1650. [13]王剛,姜民,朱明丹,等.冠心病心血瘀阻證和心腎陰虛證的蛋白組學研究[J].遼寧中醫雜志,2011,38(3):405-407. [14]盧德趙.腎陽虛大鼠肝線粒體蛋白組變化及溫補腎陽藥作用機制的研究[D].北京中醫藥大學,2008. [15]Liu F ,Seto W ,Wong D ,et al.Plasma fibronectin levels identified via quantitative proteomics profiling predicts hepatitis B surface antigen seroclearance in chronic hepatitis B[J].The Journal of Infectious Diseases,2019. [16]Dai YN,Tu YX,Meng D,et al.Serum Proteomic Changes as Candidate Biomarkers of Intermediate Liver Fibrosis in Chronic Hepatitis B Infection[J].Omics,2019,23(3):167-179. [17]Makjaroen J,Somparn P,Hodge K,et al.Comprehensive Proteomics Identification of IFN-λ3-regulated Antiviral Proteins in HBV-transfected Cells[J].Mol Cell Proteomics,2018,17(11):2197-2215. [18]She S,Yang M,Hu H,et al.Proteomics Based Identification of Autotaxin As An Anti-Hepatitis B Virus Factor and a Promoter of Hepatoma Cell Invasion and Migration[J].Cell Physiol Biochem,2018,45(2):744-760. [19]中華中醫藥學會肝膽病專業委員會,中國民族醫藥學會肝病專業委員會.慢性乙型肝炎中醫診療指南(2018年版)[J].臨床肝膽病雜志,2018,34(12):2520-2525. [20]周明德.基于藥物干預的慢性乙型肝炎肝郁脾虛證特征性蛋白的驗證研究[D].成都中醫藥大學,2017. [21]楊健坤.慢性乙型肝炎肝郁脾虛證與脾胃濕熱證血清蛋白組學驗證研究[D].成都中醫藥大學,2016. [22]楊利超.慢性乙型病毒性肝炎肝郁脾虛與脾胃濕熱證蛋白組學研究[D].成都中醫藥大學,2015. [23]Jiankun Y,Lichao Y,Baixue L,et al.iTRAQ-Based Proteomics Identification of Serum Biomarkers of Two Chronic Hepatitis B Subtypes Diagnosed by Traditional Chinese Medicine[J].Bio Med Research International,2016(2016):1-29. [24]陳文莉,羅鳴,陳小蘋,等.慢性乙型肝炎同病異證發病的分子機制:蛋白質組學分析[J].南方醫科大學學報,2016,36(3):410-413. [25]馮培民,鐘森.基于同位素標記的相對和絕對定量(iTRAQ-4plex)結合液相色譜和質譜串聯(LC-MS/MS)的蛋白質組學定量分析技術的慢性乙肝證候差異蛋白組學研究[A]//第二十九屆全國中西醫結合消化系統疾病學術會議論文集[C].2017. [26]郭芳宏.慢性乙肝中醫濕熱中阻、肝郁脾虛、瘀血阻絡證蛋白質組學初步研究[D].瀘州醫學院,2010.

相似文獻/References:

[1]林曉嵐,鄭麗花,陳苑莉,等.微信隨訪對慢性乙型肝炎患者抗病毒治療效果和 生活質量的影響研究[J].醫學信息,2018,(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
 LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Medical Information,2018,(20):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[2]林曉嵐,陳苑莉.慢性乙型肝炎患者治療依從性及其對生活質量的影響[J].醫學信息,2018,(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
 LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Medical Information,2018,(20):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[3]吳 剛,吳錦瑜.HBeAg陰性慢性乙型肝炎患者血清25-羥基維生素D3的 檢測及臨床意義[J].醫學信息,2018,(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
 WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Medical Information,2018,(20):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[4]葉向榮.恩替卡韋治療慢性乙型肝炎病毒感染的臨床價值評價[J].醫學信息,2018,(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
 YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,(20):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[5]陳仙梅,郭 碩,袁 麗,等.高發區早期賁門癌及癌前病變蛋白質組學中的應用研究[J].醫學信息,2018,(23):72.[doi:10.3969/j.issn.1006-1959.2018.23.020]
 CHEN Xian-mei,GUO Shuo,YUAN Li,et al.Application of Proteomics in Early Gastric Cardiac Cancer and Precancerous Lesions in the High Incidence Area[J].Medical Information,2018,(20):72.[doi:10.3969/j.issn.1006-1959.2018.23.020]
[6]汪曉鳳,邵和軍.慢性乙型肝炎抗病毒治療進展[J].醫學信息,2019,(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
 WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Medical Information,2019,(20):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[7]傅 蕊,李士欣,周國強,等.床旁超聲預測慢性乙型肝炎患者胃鏡檢查圍麻醉期誤吸風險的臨床價值[J].醫學信息,2019,(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
 FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Medical Information,2019,(20):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[8]張媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的臨床特點[J].醫學信息,2019,(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
 ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Medical Information,2019,(20):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[9]羅 丹,梁惠卿,吳耀南.吳耀南教授基于“伏邪”理論治療慢性乙肝的驗案舉隅[J].醫學信息,2019,(19):158.[doi:10.3969/j.issn.1006-1959.2019.19.052]
[10]陳 歡,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者 肝功能及血脂水平分析[J].醫學信息,2019,(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
 CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute, Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Medical Information,2019,(20):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]

更新日期/Last Update: 2019-10-15
重庆时时开奖号码k线图